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Abstract
Background: X-linked adrenoleukodystrophy (X-ALD; OMIM: 300100) is the most common peroxisomal disease
caused by mutations in the ATP-binding cassette, sub-family D member 1 gene or ABCD1 (geneID: 215), the coding
gene for the adrenoleukodystrophy protein (ALDP), which is an ATP-binding transport protein associated to an
active transport of very long chain fatty acids (VLCFAs). Dysfunction of ALDP induces an accumulation of VLCFAs in
all tissues leading to a neurodegenerative disorder that involves the nervous system white matter.
Case presentation: In our case report, magnetic resonance imaging (MRI) as well as the high levels of VLCFAs
prompted the diagnosis the X-ALD. Molecular analysis of ABCD1 gene have shown a pathogenic homozygous
nonsense mutation (c.1677C > G; p.(Tyr559*)) in exon 7.
Conclusion: Thus, we identified here a novel mutation in the ABCD1 gene in a Moroccan patient causing X-linked
adrenoleukodystrophy.
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Background
X-linked adrenoleukodystrophy (X-ALD; OMIM: 300100)
is the most common peroxisomal disease caused by muta-
tions in the ABCD1 (OMIM: 300371), the coding gene for
the adrenoleukodystrophy protein (ALDP) [1]. ALDP is an
ATP-binding transport protein involved in active trans-
port of enzymes or cofactors implicated in very long chain
fatty acids (VLCFAs) β-oxidation in peroxisomes. There-
fore, a slight dysfunction of ALDP induces an accumula-
tion of VLCFAs in all tissues [2]. This accumulation often
leads to a neurodegenerative disorder in the nervous sys-
tem’s white matter, axons, adrenal cortex, and testes [3] .
X-ALD is divided into two main phenotypes: The Child
Cerebral ALD (CCALD) and the adrenomyeloneuropathy
(AMN). Both of these forms may occur in the same fam-
ily. However, there is no correlation between mutations
in the gene ABCD1 and the X-ALD phenotype [4].
Epidemiological studies reported that the estimated rela-
tive frequency in males with X-ALD is 31–35 % for child-
hood cerebral ALD and 40–46 % for AMN [5]. Moreover,
the total frequency of X-ALD gene carriers is estimated to
be 1/16800 for both hemizygous males and heterozygous
women [6]. In the present study, a candidate gene ap-
proach was used to determine X-ALD related mutation in
a Moroccan patient by analyzing the entire coding region
of the ABCD1 gene by direct Sanger sequencing.
Case presentation
The patient is a 7 years and 5 months old boy who has
been adopted at birth with no information about the
biological parents, therefore we were unable to realize
an adequate family investigation with a pedigree and a
molecular analysis for the biological mother. The patient
had a normal development until he reached 6 years and
11 months old when he suddenly showed hearing diffi-
culties, a decline in visual acuity and a hyperactivity. He
also became violent and failed in school.
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The neurological examination revealed pyramidal syn-
drome of the lower limbs, walking difficulties and cere-
bellar ataxia. Besides, MRI images were consistent with
active demyelination as usually observed in childhood
cerebral ALD. A high bilateral symmetrical signal inten-
sity was detected in T2 and Flair within the pons and
midbrain. Furthermore, a low signal intensity was found
in T1 and a diffuse high signal intensity of the white
matter in T2 and Flair within the parietal-occipital area
and the splenium of corpus callosum (Fig. 1).
Visual evoked potential (VEP) and brainstem auditory
evoked potential (BAEP) tests have shown that both vis-
ual and auditory pathways evoked potential damage.
Serum cortisol level reveals that the adrenal glands were
not affected. VLCFAs analysis (Table 1) by liquid
chromatography-tandem mass spectrometry (LC-MS/
MS) revealed high levels of C24/C22 and C26/C22 ratio
in plasma.
Genomic DNA was extracted from peripheral blood
samples using standard phenol–chloroform extraction
method. The DNA concentration and purity were deter-
mined using a nanodrop spectrophotometer (NanoVue™-
NV - General Eletrics Healthcare Limited, UK). Polymer-
ase chain reaction (PCR) primer pairs of the ABCD1 cod-
ing regions were designed following the NCBI Reference
Sequence: NM_000033.3 (Table 2).
DNA sequence analysis of the ten coding exons of
ABCD1 gene, including the flanking region of each exon
(exon-intron boundaries) was performed using conven-
tional Sanger sequencing. DNA samples were first amp-
lified in a final volume of 25 μl containing: 1× reaction
buffer, 1× Q-Solution, 200 μM of each dNTP, 2 mM
MgCl2, 1 μM of primers, 2.5 U Hotstar Taq polymerase
and 50 ng of genomic DNA (Qiagen GmBH, Hilden,
Germany). PCR conditions were as follows: denaturation
at 95 °C for 15 min; 94 °C for 1 min; 60 °C- for 1 min;
and 72 °C for 1 min for 35 cycles followed by a 10 minute
final extension at 72 °C. PCR products were electropho-
resed on a 1 % agarose gel and visualized with ethidium
bromide staining under ultraviolet light to verify their size
and quantity. All the PCR products were treated with exo-
nuclease I and shrimp alkaline phosphatase enzymes prior
to sequencing according to the following protocol: 37 °C
for 40 min and 80 °C for 15 min. The sequencing reaction
was performed on the purified products using the BigDye
Terminator v 1.1 Standard Kit (Applied Biosystems,
Foster City, CA, USA). Electrophoresis of samples was
performed on the 3100 ABI Applied Biosystems sequencer
(Applied Biosystems, Foster City, CA, USA).
A mutation was identified in the exon 7 of the ABCD1
gene, with C substituted by G at nucleotide 1677, corre-
sponding to the stop codon at the residue 559.
The ALDP potentially generated by the appearance of
the stop codon exclude a part of exon 7, 8, 9 and 10
coding for the ATP binding domain (Fig. 2).
Conclusion
The first clinical case of X-linked adrenoleukodystrophy
was described by Haberfeld and Spieler in 1910 [7]. Sixty
years later, Blaw introduced the name adrenoleukodystro-
phy relative to adrenal insufficiency correlated with leuko-
dystrophy [8]. In 1981, adrenoleukodystrophy locus was
identified at the long arm of the X chromosome [9]. After-
wards, the gene related to the X-ALD (ABCD1) was iden-
tified using positional cloning strategies in 1993[1].
Fig. 1 Brain MRI of the patient with high signal intensity of the white matter in axial T2, the arrows show high signal in the corpus callosum (a),
low signal intensity of the white matter in sagittal T1 (b), low signal in the splenium of corpus callosum (arrow B) and diffuse high signal intensity
of the white matter in coronal Flair (arrows c)
Table 1 VLCFAs analysis
VLCFAs Patient Normal control
C22 mg/L 40.6 1.827 to 22.161
C22 μmol/L 119.364 5.371 to 65.153
C24 mg/L 72.8 1.228 to 18.837
C24 μmol/L 197.288 3.328 to 51.048
C26 mg/L 4.68 <1.03
C26 μmol/L 11.747 <2.585
C24/C22 ratio 1.793 0.665 to 1.008
C26/C22 ratio 0.115 0.009 to 0.069
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To date, 1605 mutations have been reported, 703 of them
are non-recurrent mutations while 162 others are nonsense
and 132 are located in exon 7 (http://www.x-ald.nl). In
our study, we identified a novel nonsense mutation in
exon 7 (c.1677C >G; p.(Tyr559*)) of a Moroccan patient,
there is also another mutation found in the same residue
by J. Haasjes & P.A.W. Mooijer in The Netherlands and
S.J.S. Steinberg in USA but the nucleotide change is in
one position behind our mutation (c.1676A > G;
p.(Tyr559Cys)), this mutation is one of the unpublished
data in the X-ALD database (http://www.x-ald.nl). No pre-
vious studies has investigated the ABCD1 gene in the
Moroccan population. Indeed, only one study reported
the same single mutation (c.659 T > C) in three families of
Moroccan Jewish descent, probably due to a founder effect
[10]. In the North African population, only two other mu-
tations (c.284C >A; p.(Ala95Asp)) and (c.1780 + 2 T >G)
of ABCD1 gene were described in Tunisian patients
[11, 12] . All these data lead us to think that the muta-
tions in the ABCD1 gene are very heterogeneous and
their identification in the North African population are
very scarce.
Nowadays, Moroccan population has better access to
MRI and dosage of VLCFA is requested as soon as the
Table 2 ABCD1 gene primers sequences
Exons Forward 5′ to 3′ Reverse 3′ to 5′ Size
1(first part) AGCAACAATCCTTCCAGCCA CACCACGTCCTCCGTCAGA 689
1(second part) CTGCTACCTTCGTCAACAG CCCACACCTTTGGCATCAG 593
2 GTGACTAGAGAGGGAGTGG GGCTTGTCTGAGTGGTAAC 657
3 CATCAGCCTGTGATGTGCTC TGGGCCTCTTGAAGTGACAG 531
4 GTGAAGAAGGCAGCCTTGG CCAGAAGCACATGGAGGTC 509
5 AGACTCCCCAGAATGCAGAG GGCTGAGGCTTGCATATGTG 216
6 CTCTCAAGGCTGGTCAGGAG CTTCACCACTTCCTGGGCCT 312
7 CGATGTGAGCGTGTGGATG GGCACCTGGCACTTTAGAC 372
8 and 9 GGAACTGAGCCAAGACCATT CTGCTGATGACAGCCGCCT 493
10 TGACCCTGTCCCTCTCCTG GCTGCTGTCTCCTTCATGTG 322
Fig. 2 Location of codon 559 in a schematic of ALDP molecular structure [13], and the sequence of the mutation (c.1677C > G; p.(Tyr559*)) in
exon 7 of the ABDC1 gene
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clinical picture is suggestive of X-linked adrenoleukodys-
trophy. Thus, we expect to have more information about
the incidence of the mutations and the frequency of
X-ALD within the Moroccan population in the near
future.
Consent
Patient was seen at the Memory Consultation group at the
CHU IBN ROCHD Neurology Department in Casablanca,
Morocco. The protocol was approved by the human ethics
committee of the CHU IBN ROCHD in accordance with
the declaration of Helsinki for experiments involving
humans and written consent was obtained the guardians
prior to the study.
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